MTSL & You
We provide experienced analysis to find sustainable values in the risky field of biotechnology investing. Timely information, clear investment advice, an industry-wide view, and top-rated performance keeps us at the forefront of all investment letters, and makes MTSL the premier tool for biotech investing. |
 |
|
John T. McCamant
Editor |
|
 |
|
Jim
McCamant
Editor at Large |
|
| John's Calendar |
4/10/08 - 5:00pm ET John McCamant interview with Pimm Foxx on Bloomberg Television on Takeda buys MLNM for $8.8 billion! Who's next?
|
|